secwatch.observer — SEC 8-K summary
======================================

Issuer:     G1 Therapeutics, Inc. (—)
CIK:        0001560241
Form:       8-K
Filed at:   2024-09-18T23:59:59+00:00
Accession:  0001193125-24-221120
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pharmacosmos completes acquisition of G1 Therapeutics for $405M; shares delisted
--------------------------------------------------------------------------------

- Tender offer expired with 39,486,447 shares (74.64%) tendered; all conditions satisfied.
- G1 stockholders receive $7.15/share cash; total equity value ~$405M.
- Shares delisted from Nasdaq; G1 becomes indirect wholly owned subsidiary of Pharmacosmos.
- Board and officers replaced; Josh Franklin named CEO of surviving corporation.
- Loan agreement with Hercules Capital repaid in full and terminated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1560241/000119312524221120/0001193125-24-221120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1560241/000119312524221120/d823642d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-221120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer